Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Hepatol. 2020 Oct 5;74(4):907–918. doi: 10.1016/j.jhep.2020.09.030

Fig. 7. High expression of ROS1/RNase7 correlates with poor survival in patients with HCC.

Fig. 7.

(A) OS and recurrence probability of patients in cohort 1 based on the status of ROS1/RNase7 expression. (B) Representative images of IHC staining for ROS1 and RNase7 expression in HCC sections from cohort 1. Scale bar, 50 μm. (C) OS and recurrence probability of patients in cohort 2. (D) Representative images of IHC staining for RNase7 and ROS1 expression in HCC sections from cohort 2. Scale bar, 50 μm. (E) ELISA analysis of RNase7 expression in plasma samples from HCC patients (n = 110) or normal individuals (n = 50). (F) Relationship between RNase7 plasma level and IHC score of ROS1/RNase7 or p-ROS1 in cohort 2. Correlations were performed using the Pearson Chi-Square test. (G) OS and recurrence probability of patients in cohort 2 based on RNase7 plasma level. (H) Relationship between RNase7 expression and IHC scores of p-ROS1 or p-ERK in cohort 1.